Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Allergic Reactions: Anaphylaxis

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...

Drug Toxicity: Allergic Reactions

Drug Toxicity: Allergic Reactions

Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Allergic Reactions

Allergic Reactions

Allergic Drug Reactions

Allergic Drug Reactions

Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Successful Treatment of Histiocytic Sarcoma in Childhood.

Cureus·2026

Same author

Local Adaptation and Osmoregulatory Mechanisms of the Copepod Acartia tonsa Under Low Salinity Stress.

Molecular ecology·2025

Same author

Reply to Liu et al., Zhou et al., and Dong et al.

American journal of respiratory and critical care medicine·2025

Same author

Pathogenic Mechanisms of Systemic Mastocytosis: Unraveling the Genetic Complexity, Bone Marrow Microenvironment, and Clinical Challenges.

European journal of haematology·2025

Same author

Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in patients with severe asthma prior to biologic initiation in real-life (STAR).

The World Allergy Organization journal·2025

Same author

Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics.

American journal of respiratory and critical care medicine·2025

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Anaphylaxis to gadobenate dimeglumine (Multihance): a case report.

Dimitrios C Kalogeromitros¹, Michael P Makris, Xenophon S Aggelides

¹Allergy Unit, Attikon Hospital, University of Athens, Athens, Greece. mak-mik@hol.gr

International Archives of Allergy and Immunology

|May 31, 2007

Summary

This study details the first reported case of anaphylaxis to gadobenate dimeglumine (Gd-BOPTA), a gadolinium-based MRI contrast agent. Diagnostic skin testing confirmed a mast cell-mediated allergic reaction to this specific agent.

Related Experiment Videos

Last Updated: Jul 14, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Area of Science:

Radiology and Imaging
Allergy and Immunology
Pharmacology

Background:

Gadolinium chelates are widely used MRI contrast agents, generally considered safe.
Severe immediate adverse effects are rare, typically limited to mild anaphylactoid reactions.
This report documents a rare instance of anaphylaxis to gadobenate dimeglumine (Gd-BOPTA).

Observation:

A 32-year-old female experienced bronchospasm and acute urticaria within one minute of Gd-BOPTA infusion during an MRI.
The patient had no prior adverse reactions to unspecified contrast media in two previous MRI scans.
Elevated serum tryptase levels and positive intradermal skin tests to Gd-BOPTA confirmed an allergic reaction.

Findings:

Skin prick tests for Gd-BOPTA were negative, but intradermal testing revealed a positive wheal-and-flare reaction.
Alternative gadolinium agents (gadodiamide, gadoteric acid) did not elicit a reaction in skin tests.
Serum tryptase levels were significantly elevated post-reaction, supporting a mast cell-mediated event.

Implications:

This case represents the first documented allergic reaction to gadobenate dimeglumine.
Intradermal skin testing is a valuable diagnostic tool for identifying specific gadolinium-based contrast agent allergies.
Findings suggest a mast cell-mediated mechanism underlying this specific contrast agent allergy.